Prevention of Staphylococcus aureus infections among surgical patients: beyond traditional perioperative prophylaxis.

[1]  T. Brennan,et al.  Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice Study I* , 2004, Quality and Safety in Health Care.

[2]  S. Cosgrove,et al.  Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  R. Wenzel,et al.  Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. , 2002, The New England journal of medicine.

[4]  V. Fraser.  Starting to Learn About the Costs of Nosocomial Infections in the New Millennium: Where Do We Go From Here? , 2002, Infection Control & Hospital Epidemiology.

[5]  M. Pfaller,et al.  Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. , 2002, Diagnostic microbiology and infectious disease.

[6]  S. Black,et al.  Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. , 2002, The New England journal of medicine.

[7]  R. Brown,et al.  Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics. , 2001, Annals of Thoracic Surgery.

[8]  H Stammer,et al.  Nasal Carriage as a Source of Staphylococcus aureus Bacteremia , 2001 .

[9]  W E Wilkinson,et al.  The Impact of Surgical-Site Infections in the 1990s: Attributable Mortality, Excess Length of Hospitalization, And Extra Costs , 1999, Infection Control & Hospital Epidemiology.

[10]  T. Henkel,et al.  Emergence of resistance during mupirocin treatment: is it a problem in clinical practice? , 1999, Journal of chemotherapy.

[11]  Wayne N. Campbell,et al.  Head-injured patients who are nasal carriers of Staphylococcus aureus are at high risk for Staphylococcus aureus pneumonia. , 1999, Critical care medicine.

[12]  L. Herwaldt.  Reduction of Staphylococcus aureus nasal carriage and infection in dialysis patients. , 1998, The Journal of hospital infection.

[13]  T. Perl,et al.  New Approaches to Reduce Staphylococcus Aureus Nosocomial Infection Rates: Treating S. Aureus Nasal Carriage , 1998, The Annals of pharmacotherapy.

[14]  A. van Belkum,et al.  Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks , 1997, Clinical microbiology reviews.

[15]  H. Verbrugh,et al.  Elimination of Nasal Carriage of Staphylococcus aureus in Hemodialysis Patients , 1996, Infection Control & Hospital Epidemiology.

[16]  Mark A. Miller,et al.  Development of Mupirocin Resistance Among Methicillin-Resistant Staphylococcus aureus After Widespread Use of Nasal Mupirocin Ointment , 1996, Infection Control & Hospital Epidemiology.

[17]  H. Verbrugh,et al.  Cost-effectiveness of perioperative mupirocin nasal ointment in cardiothoracic surgery. , 1996 .

[18]  H. Verbrugh,et al.  Reduction of Surgical-Site Infections in Cardiothoracic Surgery by Elimination of Nasal Carriage of Staphylococcus aureus , 1996, Infection Control & Hospital Epidemiology.

[19]  L. Herwaldt,et al.  Nasal and cutaneous carriage of Staphylococcus aureus in hemodialysis patients: the effect of nasal mupirocin. , 1996 .

[20]  B. Bloom,et al.  Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: a decision analysis. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  J. Ariza,et al.  Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. , 1996, The American journal of medicine.

[22]  R. Wenzel,et al.  The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. , 1995, The Journal of hospital infection.

[23]  G. Rao,et al.  Control of outbreaks of viral diarrhoea in hospitals--a practical approach. , 1995, The Journal of hospital infection.

[24]  M. Rahman,et al.  Mupirocin-resistant Staphylococcus aureus in a specialist school population. , 1994, The Journal of hospital infection.

[25]  S. Wilson,et al.  Nasal colonization with methicillin-resistant Staphylococcus aureus on admission to the surgical intensive care unit increases the risk of infection. , 1994, Anesthesia and analgesia.

[26]  J. Boelaert,et al.  Staphylococcus aureus infection in haemodialysis patients. Mupirocin as a topical strategy against nasal carriage: a review. , 1994, Journal of chemotherapy.

[27]  R. Gaynes,et al.  An overview of nosocomial infections, including the role of the microbiology laboratory , 1993, Clinical Microbiology Reviews.

[28]  B. Doebbeling,et al.  Elimination of Staphylococcus aureus Nasal Carriage in Health Care Workers: Analysis of Six Clinical Trials with Calcium Mupirocin Ointment , 1993 .

[29]  D. Rimland,et al.  Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome , 1993, Antimicrobial Agents and Chemotherapy.

[30]  V L Yu,et al.  Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. , 1993, The American journal of medicine.

[31]  R. Gaynes,et al.  Nosocomial Infections in Surgical Patients in the United States, January 1986-June 1992 , 1993, Infection Control & Hospital Epidemiology.

[32]  R. Gaynes,et al.  Nosocomial infections in surgical patients in the United States, January 1986-June 1992. National Nosocomial Infections Surveillance (NNIS) System. , 1993 .

[33]  J. Gilbart,et al.  Biochemical basis of mupirocin resistance in strains of Staphylococcus aureus. , 1992, The Journal of antimicrobial chemotherapy.

[34]  J. Boelaert,et al.  The use of nasal mupirocin ointment to prevent Staphylococcus aureus bacteraemias in haemodialysis patients: an analysis of cost-effectiveness. , 1991, The Journal of hospital infection.

[35]  W. Craig,et al.  Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[36]  T. Brennan,et al.  The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. , 1991, The New England journal of medicine.

[37]  B. Doebbeling,et al.  Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. , 1991, Annals of internal medicine.

[38]  J. Boyce,et al.  Hospital reimbursement patterns among patients with surgical wound infections following open heart surgery. , 1990, Infection control and hospital epidemiology.

[39]  V. Yu,et al.  Staphylococcus aureus nasal carriage in hemodialysis patients. Its role in infection and approaches to prophylaxis. , 1989, Archives of internal medicine.

[40]  B. Cookson,et al.  Transmissible mupirocin resistance in Staphylococcus aureus , 1989, Epidemiology and Infection.

[41]  B. Yangco,et al.  CDC definitions for nosocomial infections. , 1989, American journal of infection control.

[42]  J M Hughes,et al.  CDC definitions for nosocomial infections, 1988. , 1988, American journal of infection control.

[43]  B. Cookson,et al.  Mupirocin-resistant Staphylococcus aureus , 1987, The Lancet.

[44]  V. Yu,et al.  Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. , 1986, The New England journal of medicine.

[45]  D. Brown,et al.  Effect of rifampin and bacitracin on nasal carriers of Staphylococcus aureus , 1984, Antimicrobial Agents and Chemotherapy.

[46]  H. Maibach,et al.  Bacterial adherence to nasal mucosal cells , 1977, Infection and immunity.

[47]  E. Blair,et al.  Multiple infections among newborns resulting from colonization with Staphylococcus aureus 502A. , 1969, American journal of clinical pathology.

[48]  H. Maibach,et al.  Bacterial interference treatment of recurrent furunculosis. 2. Demonstration of the relationship of strain to pathogeneicity. , 1969, JAMA.

[49]  W. Schaffner,et al.  Bacterial interference in the therapy of recurrent staphylococcal infections. Multiple abscesses due to the implantation of the 502A strain of staphylococcus. , 1966, The New England journal of medicine.

[50]  I. Light,et al.  CONTROL OF A STAPHYLOCOCCAL OUTBREAK IN A NURSERY, USE OF BACTERIAL INTERFERENCE. , 1965, JAMA.

[51]  H. Eichenwald,et al.  BACTERIAL INTERFERENCE; PROTECTION OF ADULTS AGAINST NASAL STAPHYLOCOCCUS AUREUS INFECTION AFTER COLONIZATION WITH A HETEROLOGOUS S AUREUS STRAIN. , 1964, American journal of diseases of children.

[52]  F. E. Mayer,et al.  Declining severity of first attack of rheumatic fever. , 1963, American journal of diseases of children.

[53]  R. Rubin,et al.  The economic impact of Staphylococcus aureus infection in New York City hospitals. , 1999, Emerging infectious diseases.

[54]  J. S. Mackenzie,et al.  Emerging viral diseases: an Australian perspective. , 1999, Emerging infectious diseases.

[55]  P. Edixhoven,et al.  Prophylactic mupirocin could reduce orthopedic wound infections. 1,044 patients treated with mupirocin compared with 1,260 historical controls. , 1998, Acta orthopaedica Scandinavica.

[56]  M. Bending,et al.  Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis. Mupirocin Study Group. , 1996, Journal of the American Society of Nephrology : JASN.

[57]  L. Herwaldt,et al.  Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients. , 1993, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[58]  D. Wakefield,et al.  Methods of determining the prevalence of changes in vital signs among internal medicine inpatients. , 1993, Clinical performance and quality health care.

[59]  J Gordon,et al.  Clinical significance of methicillin-sensitive and methicillin-resistant Staphylococcus aureus in UK hospitals and the relevance of povidone-iodine in their control. , 1993, Postgraduate medical journal.

[60]  V. Yu,et al.  Failure of oral ciprofloxacin in suppressing Staphylococcus aureus carriage in haemodialysis patients. , 1992, The Journal of antimicrobial chemotherapy.

[61]  M. Schurgers,et al.  The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients. , 1989, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[62]  J. Nelson,et al.  Fatal septicemia due to Staphylococcus aureus 502A. Report of a case and review of the infectious complications of bacterial interference programs. , 1972, American journal of diseases of children.